Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group

Final Appraisal Recommendation Advice No: 1218 - July 2018

Ciprofloxacin (Cetraxal®) 2 mg/ml ear drops solution in a single dose container

Limited submission by Aspire Pharma Ltd

Recommendation of AWMSG

Ciprofloxacin (Cetraxal[®]) is recommended as an option for use within NHS Wales for the treatment of acute otitis externa in adults and children older than 1 year with an intact tympanic membrane, caused by ciprofloxacin susceptible microorganisms.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1343), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Date of first issue	July 2018
Last reviewed	December 2021

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

> All Wales Medicines Strategy Group Final Appraisal Recommendation – 1218: Ciprofloxacin (Cetraxal®). Reference number 1343. July 2018.



ww.nice.ora.uk/accreditatio

NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendations. Accreditation is valid for 5 years from October 2016. More information on accreditation can be viewed at http://www.nice.org.uk/about/what-we-do/accreditation